China has approved another coronavirus vaccine developed by the national pharmaceutical company Sinopharm for clinical trials, Report informs with reference to the company’s official statement on its Weibo social network page.
“This is a recombinant vaccine containing the elements of the coronavirus spike protein,” the company said.
According to the statement, the new drug "has enhanced properties to stimulate the body's immune defenses."
In addition to the aforementioned novelty, five more coronavirus drugs have been developed in China: three inactivated, one adenoviral, and one recombinant protein vaccine.